Modified EBP‐bFGF targeting endogenous renal extracellular matrix protects against renal ischemia‐reperfusion injury in rats.

Acute kidney injury (AKI) is a life‐threatening disease primarily caused by renal ischemia‐reperfusion (I/R) injury, which can result in renal failure. Currently, growth factor therapy is considered a promising and effective approach for AKI treatment. Basic fibroblast growth factor (bFGF), an angiogenic factor with potent activity, efficiently stimulates angiogenesis and facilitates regeneration of renal tissue. However, the unrestricted diffusion of bFGF restricts its clinical application in AKI treatment. Therefore, developing a novel sustained released system for bFGF could enhance its potential in treating AKI. In this study, we genetically engineered a multifunctional recombinant protein by fusing bFGF with a specific peptide (EBP). EBP‐bFGF effectively binds to the extracellular matrix in the injured kidney, enabling slow release of bFGF in AKI. Furthermore, following orthotopic injection into I/R rats' ischemic kidneys, EBP‐bFGF exhibited stable retention within the tissue. Additionally, EBP‐bFGF suppressed apoptosis of renal cells, reduced renal fibrosis, and facilitated recovery of renal function. These findings suggest that EBP‐bFGF delivery system represents a promising strategy for treating AKI. [ABSTRACT FROM AUTHOR]